The size of the global African horse sickness treatment market is estimated to be growing at a healthy rate during the forecast period.
The virus that causes African horse sickness (AHS) is a double-stranded, non-enveloped RNA virus that infects members of the Equidae family and is spread by midges (Culicoides spp.). Horses and mules are the ones that suffer the most. In Sub-Saharan Africa, African horse illness is endemic. AHS is strictly seasonal in subtropical locations, including South Africa. Historically, the earliest instances arose in late summer and subsequently vanished with cooler temperatures in the fall.Following the spread of the illness across the west coast of Africa or the Nile valley, AHS epidemics have occurred in various North African nations. Epidemics have also struck the Middle East and North Africa (in 1944 and 1959–1963) and southern Europe (1966 and 1987 through 1990). Midges (Culicoides spp.) transfer the illness physiologically, and they are most active at dawn and dusk. Culicoides imicola and Culicoides bolitinos are the most significant vectors in endemic regions. Other species, such as Culicoides sonorensis in the Americas and Culicoides breviaries in Australasia, should be considered vectors. The windborne dissemination of infected midges may aid the transmission of AHS. Long-distance dissemination of AHS is often caused by the unintentional transport of AHSV-infected equids. The import of infected zebra from Namibia to a safari park in Spain was linked to the 1987 AHS pandemic in southern Europe. There is currently no particular medicine for treating African horse illness, and it is suggested that horses be kept away from the disease. Supportive treatment therapy is advised for African horse sickness treatment.
The primary reasons projected to fuel the worldwide African horse sickness vaccines market are growing investment in R&D programs to develop multiple preventative vaccinations and guidelines offered by regulatory organizations related to species health for African horse sickness treatment. The availability of standard operating procedures and standards for the African horse sickness condition has been the key driver driving the African horse sickness treatment market across all regions. For numerous preventative vaccinations in research and development, the African horse sickness treatment (AHS) market is rising. A good vaccination program, in addition to a healthy dietary diet and frequent deworming, is a preventative technique for African horse illness therapy. The worldwide African horse sickness vaccines market will benefit from developing technologically sophisticated healthcare infrastructure and ongoing research efforts in collaboration with international institutions and renowned vendors to create effective vaccines. However, increased public knowledge of horse vaccination increased disposable income and favorable government policies influence market development.
The fact that even though the modified-live, multivalent vaccine is given to the horses, it does not guarantee that the horses will be completely protected from African horse sickness, only that the likelihood of the horse contracting the disease will be reduced, is a factor that is limiting the market's growth. Additionally, the market's expansion is being hampered by expensive vaccination costs.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Clinical Form, Diagnosis and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
Market Leaders Profiled |
Veterinary Serum and Vaccine Research Institute and Onderstepoort Biological Products SOC Ltd. |
Geographically, the North American market is expected to dominate the global African horse sickness treatment market and is expected to continue its dominance throughout the forecast period. Guidelines and standard operating procedures for African horse sickness illness have been important driving factors in expanding the African horse sickness treatment market in this region. In the regional market, United States recorded the largest market share of the African horse sickness treatment market. In the United States, an institution called the United States Department of Agriculture (USDA) deals with standard operating procedures for the African horse sickness illness.
European countries are also actively contributing to the market growth of African horse sickness treatment. The key market players and developed countries such as the UK, Germany, France, and Italy are contributing significant growth to the European regional market growth. The United Kingdom is the fastest growing country in the African horse sickness treatment market in Europe over the years. It is anticipated to maintain its growth during the forecast period. The rising number of research activities and availability of advanced healthcare infrastructure is influencing the market growth in the country.
The APAC African horse sickness treatment market is expected to account for a significant share globally during the forecast period. Developing healthcare infrastructure and more knowledge about horse vaccination are two aspects that contribute to market growth in the Asia Pacific region. In the future years, the African horse illness treatment market will grow rapidly across all APAC areas. The African horse illness treatment market is growing rapidly, with a slew of regional firms emerging Countries such as China and India.
Veterinary Serum and Vaccine Research Institute and Onderstepoort Biological Products SOC Ltd are a few promising companies operating in the global African horse sickness treatment market.
This market research report on the global African horse sickness treatment market has been segmented and sub-segmented into the following categories.
By Clinical Form
By Diagnosis
By Region
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region